Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹602 Cr
verified against source
Revenue YoY
29%
reported change
EBITDA
Pending
latest reported figure
Source
nse announcements
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Sai Life Sciences delivered a strong FY26 with 29% revenue growth, 56% EBITDA growth, and 109% PAT growth, driven by deepening large pharma relationships (19 of top 25, contributing 49% of revenue vs 28% in FY22) and balanced CRO/CDMO performance. The CDMO segment grew 33%, CRO 24%. Management reiterated a 15-20% revenue growth and 28-30% EBITDA margin guidance over three years, but flagged near-term headwinds from geopolitical tensions impacting input costs and logistics. A sharp capex increase to ₹1,100-1,300 crore in FY27 (vs ₹633 crore in FY26) reflects strong demand visibility from strategic customer partnerships, with 75% allocated to capacity expansion. However, execution risk remains as new capacities come online, with H2 expected stronger than H1. The key risk is that cost recovery from customers may lag cost increases, pressuring margins.
Colored figures show movement against the previous available record.
Guidance to track
- Management reiterated long-term revenue growth guidance of 15-20% CAGR, supported by strong pharma relationships and pipeline.
- Aspirational margin range of 28-30% maintained, with FY26 margin at 30% but new capacity inefficiencies expected.
- Capex guided at ₹1,100-1,300 crore, with 75% for capacity expansion (including 225kL reactor capacity) and 25% for capabilities/AI.
- Due to new capacities coming on stream progressively, second half of FY27 expected to be stronger than first half.
Risks flagged
- Input cost inflation and logistics disruptions from geopolitical tensions may not be fully recovered from customers in a timely manner, pressuring margins.
- Doubling capex to ₹1,100-1,300 crore could strain organizational capability and lead to inefficiencies, as flagged by an analyst question on execution fragility.
- Revenue from new modalities fell from 7% to 4% of total, indicating lumpiness in clinical-stage campaigns and potential competitive pressure.
- Top 10 customers contribute 54% of revenue; loss of any key customer could materially impact results.
Key quotes
- We continue to believe that our growth will be led by pharma driven by increasing outsourcing intensity, movement of biotech assets into pharma pipelines and strategic long-term partnerships.
- Our approach to capex remains science-led rather than capacity heavy, ensuring flexibility and higher long-term returns.
- The important part of being a CR and RP is to be a fast follower, be close enough to be able to change the trend but not be on the bleeding edge where you left with the dead investment.
Research modules